Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Pharmacodynamic Biomarkers of LRRK2 Activity, 2010
    Exploiting Ser910/935 Phosphorylation and 14-3-3 Binding to Develop Biomarkers for LRRK2 Activity

    Objective/Rationale: 
    There is great excitement that drugs that target an enzyme termed LRRK2 may have utility for the treatment of Parkinson’s disease. Many companies are attempting to develop LRRK2...

  • Pharmacodynamic Biomarkers of LRRK2 Activity, 2010
    Macrophage Precursors as Biomarker for LRRK2-associated Parkinson disease

    Objective/Rationale: 
    LRRK2 mutations significantly contribute to the development of Parkinson Disease, a multisystem disorder. Neuronal loss is a prerequisite to develop the disease and a crosstalk...

  • Pharmacodynamic Biomarkers of LRRK2 Activity, 2010
    Increased Dopamine Turnover as a Manifestation of LRRK2 Mutation

    Objective/Rationale: 
    Mutations in LRRK2 represent the single most important cause of dominantly inherited Parkinson’s. We have previously shown that people with LRRK2 mutations have abnormal dopamine...

  • Novel Hypotheses in Parkinson's Disease, 2010
    Characterization of PP2A as a Novel Therapeutic Target and a Biomarker of PD

    Objective/Rationale
    Protein phosphatase 2A (PP2A) is a key enzyme that dephosphorylates proteins. PP2A deficits may be critical causes of Parkinson’s disease (PD) - abnormalities in PP2A levels and...

  • Understanding LRRK2 Biology, 2010
    Characterization of LRRK2 Cellular and Signaling Pathways

    Promising Outcomes of Original Grant:
    In the original funded grant, we propose to identify LRRK2 substrates using a chemical genetics approach. We have developed suitable methods and key reagents that...

  • Alpha-Synuclein Therapeutics, 2010
    Neuroprotective efficacy of RAB3B in pre-clinical models of alpha-synucleinopathy

    Objective/Rationale
    In Parkinson’s disease, the major motor symptoms are caused by the degeneration of dopamine producing neurons in the substantia nigra pars compacta. We have identified a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.